TB-500 Research: Thymosin Beta-4 Evidence

Summary

TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring actin-sequestering protein involved in cell migration and wound repair. Research has focused on wound healing, corneal injury and cardiac repair. Thymosin beta-4 itself reached early human trials; the TB-500 fragment sold for laboratory use has not.

Last reviewed 2026-09-01

What it is

Thymosin beta-4 (Tβ4) is a 43–amino-acid protein present in most human cells and in wound fluid. TB-500 refers to a shorter synthetic fragment containing the actin-binding motif LKKTETQ, the region considered responsible for much of Tβ4's activity.

Tβ4 was isolated from thymus tissue in the early 1980s and later shown to be the major actin-sequestering molecule in mammalian cells. Clinical development for wound and corneal indications began in the 2000s.

Tβ4 is endogenous. TB-500 is produced synthetically and is a fragment, not the full protein — an important distinction when reading studies, which are overwhelmingly on full-length Tβ4.

Tβ4 concentrates in wound fluid and platelets, which suggested a natural role in repair, and it acts on cell migration rather than on proliferation alone.

How it works

In plain terms

Tβ4 binds the building blocks of the cell's internal scaffolding, keeping a pool of them free. That makes it easier for cells to change shape and crawl into a wound.

Technical detail

Tβ4 sequesters G-actin monomers, regulating the G-actin/F-actin equilibrium and enabling rapid cytoskeletal remodelling required for lamellipodia formation and directed migration. Reported downstream effects include upregulation of laminin-5, promotion of endothelial cell migration and tube formation, suppression of NF-κB-driven inflammatory signalling, and activation of epicardial progenitor cells in cardiac models.

Pathways involved

G-actin sequestration and cytoskeletal remodelling
Endothelial cell migration and angiogenesis
NF-κB-mediated inflammatory signalling suppression
Epicardial progenitor activation (cardiac models)
Laminin-5 upregulation in keratinocyte migration

Current research

Laboratory research

Cell studies consistently show accelerated keratinocyte and endothelial migration in scratch-wound assays and increased tube formation in angiogenesis assays.

Animal research

Rodent and rabbit models report faster dermal wound closure, reduced scarring, improved corneal epithelial repair, and functional improvement after induced myocardial infarction. Equine tendon studies exist but are small.

Human research

Full-length Tβ4 progressed to Phase 2 trials for dry eye disease and neurotrophic keratopathy, with acceptable tolerability reported. Dermal wound-healing trials produced mixed results. The TB-500 fragment specifically has not been through published human efficacy trials.

Ongoing research

Ophthalmic Tβ4 development has been the most persistent clinical thread; consult the registry for current status.

What is being investigated

Dermal wound closure and scar quality in animal models
Corneal epithelial repair and dry eye (human trials of full-length Tβ4)
Cardiac repair after experimental infarction
Tendon and ligament recovery in veterinary models
Hair follicle activation in rodent studies
Reduction of inflammatory signalling at injury sites

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Most published data uses full-length thymosin beta-4, not the TB-500 fragment — findings are not automatically transferable
No published human efficacy trials of the fragment
Long-term safety unknown; the actin and migration pathways it influences are also involved in metastasis, an unresolved theoretical concern
TB-500 is prohibited in sport by WADA under the peptide hormones and growth factors category
Human pharmacokinetics for the fragment are uncharacterised

Evidence ratings

Laboratory studies

Strong

Actin-sequestration and migration effects are well established for Tβ4.

Animal studies

Moderate

Consistent wound and cardiac findings across several models.

Human studies

Limited

Phase 2 ophthalmic data for Tβ4; none for the TB-500 fragment.

Long-term safety

None

No chronic human exposure data.

Comparisons

BPC-157 vs TB-500

Different mechanisms, frequently confused.

References

[1]Thymosin beta-4 — indexed literature — PubMed, 1981–present
[2]Thymosin beta-4 and wound healing — PubMed, 1999–present
[3]Thymosin beta-4 cardiac repair — PubMed, 2004–present
[4]Registered trials — thymosin beta-4 — ClinicalTrials.gov, current
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is TB-500?+

A synthetic fragment of thymosin beta-4 containing the actin-binding motif LKKTETQ, studied in the context of cell migration and tissue repair.

Is TB-500 the same as thymosin beta-4?+

No. Tβ4 is the full 43–amino-acid protein; TB-500 is a shorter fragment. Almost all published research uses the full protein.

Is TB-500 FDA approved?+

No. Neither TB-500 nor full-length thymosin beta-4 is an approved medicine.

How does TB-500 work?+

Through actin sequestration, which allows the cytoskeletal remodelling cells need in order to migrate into a wound, plus reported angiogenic and anti-inflammatory effects.

Is TB-500 banned in sport?+

Yes. WADA prohibits it at all times under section S2, peptide hormones, growth factors and related substances.

What human trials exist?+

Full-length Tβ4 reached Phase 2 for dry eye and neurotrophic keratopathy. Dermal wound trials were mixed. The fragment has no published efficacy trials.

Does TB-500 help tendons?+

Veterinary and rodent tendon studies report improved healing markers, but the studies are small and human data does not exist.

Is TB-500 a growth factor?+

Not in the classical sense. It does not bind a growth-factor receptor; it acts intracellularly on actin dynamics.

Why is TB-500 often paired with BPC-157 in discussions?+

Both are discussed in repair contexts, but their proposed mechanisms are distinct — angiogenic signalling versus cytoskeletal regulation. No controlled study has tested the combination in humans.

Continue your research

What Is BPC-157?

The other widely discussed repair peptide

GHK-Cu and matrix remodelling

Peptides and recovery research